KR20170040351A - Nmda 조절인자를 사용하여 우울증을 치료하는 방법 - Google Patents

Nmda 조절인자를 사용하여 우울증을 치료하는 방법 Download PDF

Info

Publication number
KR20170040351A
KR20170040351A KR1020177006761A KR20177006761A KR20170040351A KR 20170040351 A KR20170040351 A KR 20170040351A KR 1020177006761 A KR1020177006761 A KR 1020177006761A KR 20177006761 A KR20177006761 A KR 20177006761A KR 20170040351 A KR20170040351 A KR 20170040351A
Authority
KR
South Korea
Prior art keywords
depression
patient
weeks
period
glyx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177006761A
Other languages
English (en)
Korean (ko)
Inventor
론 버치
Original Assignee
노렉스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노렉스, 인크. filed Critical 노렉스, 인크.
Publication of KR20170040351A publication Critical patent/KR20170040351A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177006761A 2014-08-14 2015-08-13 Nmda 조절인자를 사용하여 우울증을 치료하는 방법 Ceased KR20170040351A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462037374P 2014-08-14 2014-08-14
US62/037,374 2014-08-14
PCT/US2015/045071 WO2016025721A1 (en) 2014-08-14 2015-08-13 Methods of treating depression using nmda modulators

Publications (1)

Publication Number Publication Date
KR20170040351A true KR20170040351A (ko) 2017-04-12

Family

ID=55304631

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177006761A Ceased KR20170040351A (ko) 2014-08-14 2015-08-13 Nmda 조절인자를 사용하여 우울증을 치료하는 방법

Country Status (18)

Country Link
US (1) US20170296616A1 (cg-RX-API-DMAC7.html)
EP (1) EP3180015A4 (cg-RX-API-DMAC7.html)
JP (2) JP2017524721A (cg-RX-API-DMAC7.html)
KR (1) KR20170040351A (cg-RX-API-DMAC7.html)
CN (1) CN106659763A (cg-RX-API-DMAC7.html)
AU (2) AU2015301650A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017002930A2 (cg-RX-API-DMAC7.html)
CA (1) CA2957937A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017000378A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017002356A2 (cg-RX-API-DMAC7.html)
IL (1) IL250557A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017002052A (cg-RX-API-DMAC7.html)
PH (1) PH12017500275A1 (cg-RX-API-DMAC7.html)
RU (1) RU2017107033A (cg-RX-API-DMAC7.html)
SG (2) SG10201810016XA (cg-RX-API-DMAC7.html)
UA (1) UA123623C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016025721A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701526B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180102052A (ko) * 2015-10-16 2018-09-14 노오쓰웨스턴 유니버시티 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
US10487055B2 (en) 2016-06-01 2019-11-26 Rhode Island Board Of Education Diindole compounds useful in treatment of nervous system disorders
US11358935B2 (en) 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
EP3706734A1 (en) * 2017-11-10 2020-09-16 Naurex Inc. Methods of administration of nmda receptor agonists
US20200368310A1 (en) * 2017-12-05 2020-11-26 Naurex, INC Treatment with nmda receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
EP2485751B1 (en) * 2009-10-05 2014-05-21 Northwestern University GLYX-13 for use in a method of treating refractory depression
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans

Also Published As

Publication number Publication date
BR112017002930A2 (pt) 2017-12-05
CL2017000378A1 (es) 2017-11-03
SG10201810016XA (en) 2018-12-28
MX2017002052A (es) 2018-08-15
EP3180015A4 (en) 2018-02-14
JP2020128391A (ja) 2020-08-27
IL250557A0 (en) 2017-03-30
CO2017002356A2 (es) 2017-06-09
AU2015301650A1 (en) 2017-03-23
PH12017500275A1 (en) 2017-07-03
ZA201701526B (en) 2018-05-30
EP3180015A1 (en) 2017-06-21
JP2017524721A (ja) 2017-08-31
UA123623C2 (uk) 2021-05-05
SG11201701134XA (en) 2017-03-30
RU2017107033A3 (cg-RX-API-DMAC7.html) 2019-02-12
US20170296616A1 (en) 2017-10-19
CA2957937A1 (en) 2016-02-18
RU2017107033A (ru) 2018-09-14
AU2020203165A1 (en) 2020-06-04
WO2016025721A1 (en) 2016-02-18
CN106659763A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
AU2020203165A1 (en) Methods of treating depression using NMDA modulators
CN106562952B (zh) 氯胺酮在治疗重性抑郁障碍中的应用
JP2021527092A5 (cg-RX-API-DMAC7.html)
CN106999467A (zh) 治疗认知减退的方法
KR20120104422A (ko) 중추신경계 (cns) 자가면역 탈수초 질환의 치료 또는 예방을 위한 디아족사이드
EA028300B1 (ru) Композиции, содержащие вортиоксетин и донепезил
WO2011131705A1 (en) Treatment of multiple sclerosis with masitinib
CN109350616B (zh) I-brd9或其衍生物在制备抗癫痫药物中的应用
US20160345855A1 (en) Methods of treating brain disorders or identifying biomarkers related thereto
JP7527662B2 (ja) ピモジドとメトトレキサートの医薬組成物、及びその使用
JP7233741B2 (ja) 炎症反応を伴う疼痛状態における鎮痛のための末梢限局的二重作用性κおよびδオピオイドアゴニスト
US12502371B2 (en) Drug for treating and preventing dementia
AU2013301125B2 (en) A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
CN112972462B (zh) 帕比司他在制备预防、缓解和/或治疗多发性硬化症药物中的应用
JP2017088584A (ja) 医薬組成物
JP2024030188A (ja) 女性のうつ症状を改善するための医薬組成物
JP2008513430A (ja) 月経前症候群および月経前不快気分障害の処置のためのピンドロール
HK40093852A (en) Combinations of opioids and n-acylethanolamines
US20190351006A1 (en) Methods of administration of nmda receptor agonists
CN101151051A (zh) 钠通道阻断剂及其衍生物与阿片受体拮抗剂的联合制剂
WO2005099697A1 (fr) Utilisation d'hydrochlorure de phenylcynonate dans le traitement ou l'attenuation des symptomes de l'epilepsie
JP2018002681A (ja) 医薬組成物
HK1237649A1 (zh) Nmdar调节化合物的组合

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170310

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200811

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220308

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220810

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220308

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I